Lead Product(s) : CM313
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : CM313
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CM355
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : CM355
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hetrombopag Olamine
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2018
Lead Product(s) : Hetrombopag Olamine
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable